About Clarity

Clarity is a clinical-stage radiopharmaceutical company developing next-generation products to address the growing need for radiopharmaceuticals in oncology.

Clarity is a global leader in next-generation radiopharmaceuticals with its Targeted Copper Theranostic (TCT) platform of products. Clarity’s products use the “perfect pairing” of copper isotopes, copper-64 (Cu-64 or 64Cu) for imaging and copper-67 (Cu-67 or 67Cu) for therapy, which deliver a compelling combination of high accuracy and high precision in the treatment of a range of cancers, as well as providing supply and logistical advantages over current-generation theranostics. TCT provide a highly efficacious, scalable, and cost-effective way to expand radiopharmaceuticals into the global oncology market.

Product Development

Clarity’s three core clinical-stage theranostic products, SAR-bisPSMA, SAR-Bombesin and SARTATE, each contain a different targeting agent that binds to specific receptors that are present on different cancer cells.

The three theranostic products are in clinical development for both the diagnosis and treatment of various cancers addressing unmet clinical needs.

The versatility of the SAR Technology platform enables Clarity to pursue a Discovery Program focused on developing new products and new intellectual property (IP) for a range of indications of cancer. Clarity has a robust IP position with a broad patent portfolio covering its platform, pipeline and products.